Literature DB >> 6173539

Pharmacological control of platelet and red blood cell function in the microcirculation.

F De Clerck, J L David.   

Abstract

Mesh：

Substances：

Year:  1981        PMID： 6173539     DOI： 10.1097/00005344-198111000-00026

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN： 0160-2446            Impact factor:   3.105


× No keyword cloud information.
  16 in total

1.  Release of a neutrophil-derived vasoconstrictor agent which augments platelet-induced contractions of blood vessels in vitro.

Authors:  W C Sessa; K M Mullane
Journal:  Br J Pharmacol       Date:  1990-03       Impact factor: 8.739

Review 2.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

3.  Biochemical mechanisms in 5-hydroxytryptamine-induced human platelet aggregation.

Authors:  F de Clerck; B Xhonneux; R van de Wiele
Journal:  Agents Actions       Date:  1985-12

4.  Influence of ketanserin on glucose and lipid metabolism in diabetic patients with hypertension.

Authors:  H U Janka; H Mehnert; R Fisher; K U Seiler
Journal:  Drugs       Date:  1988       Impact factor: 9.546

5.  Regulation of the L-type calcium channel alpha-1 subunit by chronic depolarization in the neuron-like PC12 and aortic smooth muscle A7r5 cell lines.

Authors:  O Feron; T Godfraind
Journal:  Pflugers Arch       Date:  1995-07       Impact factor: 3.657

6.  Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R 41,468), a selective 5-HT2-receptor antagonist. 1982.

Authors:  F de Clerck; J L David; P A Janssen
Journal:  Agents Actions       Date:  1994-12

Review 7.  Blood platelets in human essential hypertension.

Authors:  F De Clerck
Journal:  Agents Actions       Date:  1986-08

8.  Platelet activation by endogenous 5-hydroxytryptamine and histamine released by mast cell degranulation with compound 48/80 in the rat.

Authors:  F De Clerck; Y Somers; L Van Gorp; B Xhonneux
Journal:  Agents Actions       Date:  1983-02

Review 9.  Flunarizine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use.

Authors:  B Holmes; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-01       Impact factor: 9.546

10.  Inhibition of thrombocyte aggregation by oral motapizone and other drugs.

Authors:  V Schulz; W Fischer; U Hanselle; W Huhmann; V Zietsch
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.